'Extra Time' podcast. In conversation with Dr Annalisa Jenkins

Published

08 Mar 2021

Author

Dr Annalisa Jenkins & Dr Adam M Hill

Annalisa’s inspirational career spans over 25 years in the global biopharma industry – she started her career at St Barts, in London, where she trained as a cardiologist, before joining the British Royal Navy as a medical officer during the Gulf Conflict, achieving the rank of surgeon lieutenant commander during her time there.

Annalisa spent almost two decades producing a pipeline of innovation at Bristol Myers Squibb and Merck Serono – she has built and led scientific, regulatory and medical affairs teams to advance programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally.

More recently, Annalisa, has focussed her experience on building and financing biotech companies, pursuing cures for the most challenging rare diseases and working to address important medical issues globally. She served as President and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx in 2017.

Annalisa is a committee member of the Science Board to the U.S. Food & Drug Administration, board member at Faster Cures, a centre of The Milken Institute and Chair of The Court at The London School of Hygiene and Tropical Medicine.

She also sits on the board of many growing companies and is a fierce champion for diversity and inclusion, particularly for women in science.

Subscribe to the podcast

I think that integrating diagnostics to better understand how to match these therapies with the right patients is absolutely going to be the way that this whole space moves forward... We truly are entering the world in the future of individual patients; the best drug for the best patient, at the best time, in the right dose. Inevitably, all of that will come to fruition as we truly understand a baseline.

Dr Annalisa Jenkins